FRANKLIN LAKES, N.J. - BD (Becton, Dickinson and Company) (NYSE:BDX), a global medical technology firm, has entered a collaboration with Hamilton, a leader in laboratory automation technology. This partnership is aimed at developing automated applications and robotics-compatible reagent kits to enhance the standardization and accuracy of large-scale single-cell multiomics experiments.
The collaboration seeks to integrate Hamilton's robotic technology with BD's suite of BD Rhapsody™ Single-Cell Analysis Library Preparation Reagent Kits. This integration is expected to automate critical steps such as pipetting and thermal cycling, leading to the creation of DNA libraries prepared for genetic sequencing.
Single-cell multiomics, a method that provides comprehensive data by analyzing multiple biomolecular layers from individual cells, is vital for research in various fields including oncology and immunology. The process to prepare libraries for next-generation sequencing (NGS) is complex and prone to variability due to manual operations, which can affect data quality and results consistency.
Steve Conly, worldwide president at BD Biosciences, emphasized the importance of reproducible results in multiomics assays and expressed that the collaboration aims to empower researchers to conduct extensive single-cell multiomics studies with greater confidence. Matt Hamilton, Vice CEO at Hamilton, underscored the goal of providing a complete solution that minimizes biases and enhances the reliability of results in high-throughput experiments.
The development and release of the BD Rhapsody™ Single-Cell Analysis Library Preparation Reagent Kits and Hamilton Microlab® NGS STAR™ applications are scheduled to begin in phases starting in 2024.
BD is recognized for its commitment to advancing medical discovery and care delivery by developing innovative technologies and solutions. With a global presence and a workforce exceeding 70,000, BD strives to address some of the most pressing health issues worldwide.
This news is based on a press release statement and reflects the ongoing efforts within the medical technology sector to improve research methodologies through automation and collaboration.
InvestingPro Insights
As BD (Becton, Dickinson and Company) announces its collaboration with Hamilton to advance single-cell multiomics research, the financial health and market performance of the company remains a key interest for investors. BD's commitment to innovation is matched by its strong financial track record, which includes a consistent dividend history. The company has raised its dividend for 53 consecutive years, showcasing a stable financial policy that investors often associate with reliable long-term performance. Moreover, analysts are anticipating growth in net income this year, reflecting confidence in the company's profitability.
On the valuation front, BD's current market capitalization stands at $68.3B, with a Price/Earnings (P/E) ratio of 47.45, which adjusts to 32.76 based on the last twelve months as of Q4 2023. The company also reported a revenue growth of 2.66% over the same period, indicating a steady upward trend in its financial performance.
For investors seeking additional insights and analysis, InvestingPro offers comprehensive metrics and expert tips. Currently, there are over 9 additional InvestingPro Tips available for BD, which can be accessed through an InvestingPro+ subscription. The service is now on a special New Year sale with discounts of up to 50%. Use coupon code SFY24 to get an additional 10% off a 2-year InvestingPro+ subscription, or SFY241 to get an additional 10% off a 1-year subscription. These tips and data can provide valuable context for investors evaluating BD's stock in light of its latest strategic partnership.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.